Neurocrine Biosciences Inc
NASDAQ:NBIX

Watchlist Manager
Neurocrine Biosciences Inc Logo
Neurocrine Biosciences Inc
NASDAQ:NBIX
Watchlist
Price: 125.88 USD 0.7% Market Closed
Market Cap: 12.7B USD
Have any thoughts about
Neurocrine Biosciences Inc?
Write Note

Neurocrine Biosciences Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Neurocrine Biosciences Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Neurocrine Biosciences Inc
NASDAQ:NBIX
Net Income (Common)
$385.9m
CAGR 3-Years
-5%
CAGR 5-Years
79%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$126m
CAGR 3-Years
-74%
CAGR 5-Years
-46%
CAGR 10-Years
-35%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Neurocrine Biosciences Inc
Glance View

Market Cap
12.7B USD
Industry
Biotechnology

Neurocrine Biosciences Inc. is a biopharmaceutical company committed to improving the lives of those suffering from neurological and endocrine disorders. Founded in 1992 and based in San Diego, California, Neurocrine has carved out a niche in developing innovative therapies that target complex medical conditions. Its flagship product, Ingrezza (valbenazine), has rapidly gained traction as a leading treatment for tardive dyskinesia, a movement disorder often caused by long-term antipsychotic medication use. This success has propelled the company into the limelight and established it as a key player in the CNS (central nervous system) market. Investors are captivated by Neurocrine’s strong clinical pipeline, promising research partnerships, and an agile operational approach that enable it to adapt swiftly to the evolving landscape of biopharma. The company’s growth story is further enhanced by its commitment to expanding its product portfolio. With therapies in development for conditions such as endometriosis and other hormonal disorders, Neurocrine is not just a one-hit wonder; it is poised to become a powerhouse in the biotech domain. Boasting a robust financial position, the company leverages its research capabilities to identify and bring forward transformative treatments. For investors, Neurocrine represents an opportunity at the intersection of science and compassion, as it continually strives to address unmet medical needs with its innovative solutions. With strong leadership and a dedication to breakthrough therapies, the company stands ready to capitalize on the growing demand for specialized medications within the healthcare landscape.

NBIX Intrinsic Value
142.27 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

What is Neurocrine Biosciences Inc's Net Income (Common)?
Net Income (Common)
385.9m USD

Based on the financial report for Sep 30, 2024, Neurocrine Biosciences Inc's Net Income (Common) amounts to 385.9m USD.

What is Neurocrine Biosciences Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
79%

Over the last year, the Net Income (Common) growth was 102%. The average annual Net Income (Common) growth rates for Neurocrine Biosciences Inc have been -5% over the past three years , 79% over the past five years .

Back to Top